CLINICAL_TRIALS
trial_result
· 2017-03-10
Clinical Trial Update: Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018 [Phase 3]
Summary
A Phase 3 clinical trial (NX02-0018) evaluating NX-1207 for benign prostatic hyperplasia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Nymox Corporation | Conditions: Benign Prostatic Hyperplasia (BPH) | Phase 3 | Status: COMPLETED